Loading...
Market
Story
Eli Lilly's Zepbound and Mounjaro Cut Diabetes Risk by 94% with Weekly Injections
Aug 20, 2024, 12:19 PM
Eli Lilly's weight-loss drug, Zepbound, has shown a significant reduction in the risk of developing type 2 diabetes in a long-term study. The three-year SURMOUNT-1 trial demonstrated that adults with pre-diabetes and obesity or overweight who took tirzepatide, the active ingredient in Zepbound, had a 94% lower risk of progressing to diabetes compared to those on a placebo. Additionally, patients on the highest dose of Zepbound experienced an average weight loss of 22.9% over 176 weeks. These findings bolster the case for the long-term use of Zepbound and Mounjaro in managing obesity and preventing diabetes. The study involved weekly injections of the medication.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
